Amgen (AMGN) Stock Analysis & Winston Score
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-rel
Winston Score: 61/100 — Good
A decent business — some strong pillars, some weaker.
- Quality: Good (19/30)
- Growth: Exceptional (18/20)
- Cash Flow: Exceptional (10/10)
- Stability: Mixed (3/10)
- Valuation: Strong (7/10)
- Ownership: Weak (1/15)


